

# Brenda M Sandmaier

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7069826/publications.pdf>

Version: 2024-02-01

394  
papers

26,988  
citations

9234

74  
h-index

6630

156  
g-index

398  
all docs

398  
docs citations

398  
times ranked

13413  
citing authors

#	ARTICLE	IF	CITATIONS
1	Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and <i>t(8;21) KMT2A</i> -rearranged AML. <i>Blood Advances</i> , 2022, 6, 828-847.	2.5	5
2	Megadose 90Y-ibritumomab tiuxetan prior to allogeneic transplantation is effective for aggressive large B-cell lymphoma. <i>Blood Advances</i> , 2022, 6, 37-45.	2.5	3
3	Outcomes after hematopoietic cell transplantation among non-English- compared to English-speaking recipients. <i>Bone Marrow Transplantation</i> , 2022, 57, 440-444.	1.3	3
4	Conditioning intensity and peritransplant flow cytometric MRD dynamics in adult AML. <i>Blood</i> , 2022, 139, 1694-1706.	0.6	36
5	Utility of the Treatment-Related Mortality (TRM) score to predict outcomes of adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation. <i>Leukemia</i> , 2022, 36, 1563-1574.	3.3	2
6	Development of [211At]astatine-based anti-CD123 radioimmunotherapy for acute leukemias and other CD123+ malignancies. <i>Leukemia</i> , 2022, 36, 1485-1491.	3.3	6
7	Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: Improved outcomes over two decades. <i>Haematologica</i> , 2021, 106, 1599-1607.	1.7	18
8	90Y-labeled anti-CD45 antibody allogeneic hematopoietic cell transplantation for high-risk multiple myeloma. <i>Bone Marrow Transplantation</i> , 2021, 56, 202-209.	1.3	6
9	Yttrium-90 Anti-CD45 Immunotherapy Followed by Autologous Hematopoietic Cell Transplantation for Relapsed or Refractory Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 57.e1-57.e8.	0.6	7
10	Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myelogenous Leukemia and Myelodysplastic Syndromes with Low/Intermediate but not High Disease Risk Index: A Center for International Blood and Marrow Transplant Research Study. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 68.e1-68.e9.	0.6	15
11	Blood and marrow transplantation during the emerging COVID-19 pandemic: the Seattle approach. <i>Bone Marrow Transplantation</i> , 2021, 56, 305-313.	1.3	3
12	Long-term Outcomes with Nonmyeloablative HLA-Identical Related Hematopoietic Cell Transplantation Using Tacrolimus and Mycophenolate Mofetil for Graft-versus-Host Disease Prophylaxis. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 163.e1-163.e7.	0.6	0
13	Addition of Astatine-211-Labeled Anti-CD45 Antibody to TBI as Conditioning for DLA-Identical Marrow Transplantation: A Novel Strategy to Overcome Graft Rejection in a Canine Presensitization Model: <i>Radioimmunotherapy to Overcome Transfusion-Induced Sensitization</i> . <i>Transplantation and Cellular Therapy</i> , 2021, 27, 476.e1-476.e7.	0.6	4
14	Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR. <i>Leukemia</i> , 2021, 35, 2076-2085.	3.3	28
15	Effect of post-treatment MRD status on subsequent outcomes according to chemotherapy intensity in acute myeloid leukemia (AML). <i>Leukemia and Lymphoma</i> , 2021, 62, 1532-1535.	0.6	3
16	Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 2108-2117.	1.3	6
17	Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia. <i>Blood</i> , 2021, 138, 387-400.	0.6	26
18	Allogeneic Transplantation to Treat Therapy-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Adults. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 923.e1-923.e12.	0.6	15

#	ARTICLE	IF	CITATIONS
19	EASIX and mortality after allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2020, 55, 553-561.	1.3	70
20	Phase I/II multisite trial of optimally dosed clofarabine and low-dose TBI for hematopoietic cell transplantation in acute myeloid leukemia. <i>American Journal of Hematology</i> , 2020, 95, 48-56.	2.0	5
21	Rituximab-based allogeneic transplant for chronic lymphocytic leukemia with comparison to historical experience. <i>Bone Marrow Transplantation</i> , 2020, 55, 172-181.	1.3	10
22	Comparative analysis of total body irradiation (TBI)-based and non-TBI-based myeloablative conditioning for acute myeloid leukemia in remission with or without measurable residual disease. <i>Leukemia</i> , 2020, 34, 1701-1705.	3.3	15
23	Impact of Peri-Transplant Rituximab and Host/Donor Fc Receptor Polymorphisms for Patients with Relapsed or Refractory CD20+ B-Cell Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S226-S227.	2.0	0
24	Survival, Nonrelapse Mortality, and Relapse-Related Mortality After Allogeneic Hematopoietic Cell Transplantation: Comparing 2003-2007 Versus 2013-2017 Cohorts. <i>Annals of Internal Medicine</i> , 2020, 172, 229.	2.0	157
25	Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. <i>Blood Advances</i> , 2020, 4, 3180-3190.	2.5	18
26	Impact of Rituximab and Host/Donor Fc Receptor Polymorphisms after Allogeneic Hematopoietic Cell Transplantation for CD20+ B Cell Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1811-1818.	2.0	4
27	Conditioning Intensity, Pre-Transplant Flow Cytometric Measurable Residual Disease, and Outcome in Adults with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation. <i>Cancers</i> , 2020, 12, 2339.	1.7	28
28	Therapy of Myeloid Leukemia using Novel Bispecific Fusion Proteins Targeting CD45 and 90Y-DOTA. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 2575-2584.	1.9	7
29	AML-145: Multicenter 11-Year Experience of Outcomes After Intensive Versus Less-Intensive Therapy for Patients with Acute Myeloid Leukemia: Focus on Older and Medically Infirm Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, S185.	0.2	0
30	Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research. <i>Haematologica</i> , 2020, 105, 1329-1338.	1.7	23
31	Biokinetics of Radiolabeled Monoclonal Antibody BC8: Differences in Biodistribution and Dosimetry Among Hematologic Malignancies. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1300-1306.	2.8	4
32	Sirolimus with CSP and MMF as GVHD prophylaxis for allogeneic transplantation with HLA antigen-mismatched donors. <i>Blood</i> , 2020, 136, 1499-1506.	0.6	16
33	Impact of pretransplant measurable residual disease on the outcome of allogeneic hematopoietic cell transplantation in adult monosomal karyotype AML. <i>Leukemia</i> , 2020, 34, 1577-1587.	3.3	22
34	HLA-Haploidentical Hematopoietic Cell Transplantation for Treatment of Nonmalignant Diseases Using Nonmyeloablative Conditioning and Post-Transplant Cyclophosphamide. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1332-1341.	2.0	24
35	MLL-Rearranged AML Is Associated with Poor Outcomes As Compared to Patients with Intermediate- and Adverse-Risk Disease: A CIBMTR Study of 3779 Adult Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S10-S11.	2.0	0
36	Yttrium-90-labeled anti-CD45 antibody followed by a reduced-intensity hematopoietic cell transplantation for patients with relapsed/refractory leukemia or myelodysplasia. <i>Haematologica</i> , 2020, 105, 1731-1737.	1.7	20

#	ARTICLE	IF	CITATIONS
37	Allogeneic Hematopoietic Cell Transplantation in the Outpatient Setting. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2152-2159.	2.0	14
38	Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial. <i>Lancet Haematology</i> , 2019, 6, e409-e418.	2.2	84
39	Phase I Study of a CD45-Targeted Antibody-Radionuclide Conjugate for High-Risk Lymphoma. <i>Clinical Cancer Research</i> , 2019, 25, 6932-6938.	3.2	15
40	Total body irradiation dose escalation decreases risk of progression and graft rejection after hematopoietic cell transplantation for myelodysplastic syndromes or myeloproliferative neoplasms. <i>Haematologica</i> , 2019, 104, 1221-1229.	1.7	14
41	Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60-75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study. <i>Leukemia</i> , 2019, 33, 2599-2609.	3.3	76
42	HLA-Matched Sibling Versus Haploidentical Hematopoietic Cell Transplantation (HCT) in Patients with Acute Myeloid Leukemia (AML) in First Complete Remission (CR1). <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S59-S60.	2.0	0
43	Total body irradiation dose and risk of subsequent neoplasms following allogeneic hematopoietic cell transplantation. <i>Blood</i> , 2019, 133, 2790-2799.	0.6	81
44	Limitations to Receiving Allogeneic Hematopoietic Cell Transplantation for Treatment of Acute Myeloid Leukemia: A Large Multi-Center Prospective Longitudinal Observational Study. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S115-S116.	2.0	0
45	Pre-transplant bone marrow monocytic myeloid-derived suppressor cell frequency is not associated with outcome after allogeneic hematopoietic cell transplantation for acute myeloid leukemia in remission. <i>Bone Marrow Transplantation</i> , 2019, 54, 1511-1514.	1.3	1
46	Comparison of characteristics and outcomes of late acute and NIH chronic GVHD between Japanese and white patients. <i>Blood Advances</i> , 2019, 3, 2764-2777.	2.5	12
47	The $\beta$ -emitter astatine-211 targeted to CD38 can eradicate multiple myeloma in a disseminated disease model. <i>Blood</i> , 2019, 134, 1247-1256.	0.6	30
48	The impact of the graft-versus-leukemia effect on survival in acute lymphoblastic leukemia. <i>Blood Advances</i> , 2019, 3, 670-680.	2.5	71
49	Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission. <i>Blood Advances</i> , 2019, 3, 1826-1836.	2.5	89
50	Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy. <i>Blood Advances</i> , 2019, 3, 3062-3069.	2.5	74
51	Disability related to chronic graft-versus-host disease after alternative donor hematopoietic cell transplantation. <i>Haematologica</i> , 2019, 104, 835-843.	1.7	18
52	Low-Dose Azacitidine with DNMT1 Level Monitoring to Treat Post-Transplantation Acute Myelogenous Leukemia or Myelodysplastic Syndrome Relapse. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1122-1127.	2.0	10
53	Prognostic Performance of the Augmented Hematopoietic Cell Transplantation-Specific Comorbidity/Age Index in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation from Alternative Graft Sources. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1045-1052.	2.0	19
54	Long-term follow up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma. <i>Haematologica</i> , 2019, 104, 380-391.	1.7	25

#	ARTICLE	IF	CITATIONS
55	Impact of Depth of Pretransplant Clinical Response on Outcomes of Acute Myeloid Leukemia Patients in First Complete Remission (AML-CR1) Who Undergo Allogeneic Hematopoietic Cell Transplantation (AlloHCT). <i>Blood</i> , 2019, 134, 4585-4585.	0.6	1
56	Superior Survival with Post-Remission Pediatric-Inspired Chemotherapy Compared to Myeloablative Allogeneic Hematopoietic Cell Transplantation in Adolescents and Young Adults with Ph-Negative Acute Lymphoblastic Leukemia in First Complete Remission: Comparison of CALGB 10403 to Patients Reported to the CIBMTR. <i>Blood</i> , 2019, 134, 261-261.	0.6	5
57	Allogeneic Hematopoietic Stem Cell Transplantation for Therapy-Related Myelodysplastic Syndromes and Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 2036-2036.	0.6	1
58	Myeloablative Conditioning Is Preferred for Allogeneic Transplantation of Acute Myeloid Leukemia and Myelodysplastic Syndromes with Low/Intermediate but Not High Disease Risk Index. <i>Blood</i> , 2019, 134, 4603-4603.	0.6	0
59	Comparative Analysis of Total Body Irradiation (TBI)-Based and Non-TBI-Based Myeloablative Conditioning for Acute Myeloid Leukemia in Remission with and without Measurable Residual Disease. <i>Blood</i> , 2019, 134, 321-321.	0.6	0
60	Sirolimus Combined with Cyclosporine (CSP) and Mycophenolate Mofetil (MMF) As Graft-Vs-Host Disease (GVHD) Prophylaxis after Nonmyeloablative (NMA) Hematopoietic Cell Transplantation (HCT) Using HLA Class I or Class II Antigen Mismatched Donors: Results from a Phase II Multi-Center Trial. <i>Blood</i> , 2019, 134, 369-369.	0.6	0
61	Inosine Monophosphate Dehydrogenase Pharmacogenetics in Hematopoietic Cell Transplantation Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1802-1807.	2.0	9
62	Late Effects and Patient Reported Quality of Life by Donor Source at 3 Years in Patients Surviving at Least 1 Year Following Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S29.	2.0	0
63	Pretransplant Consolidation Is Not Beneficial for Adults with ALL Undergoing Myeloablative Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 945-955.	2.0	7
64	Description and prognostic significance of the kinetics of minimal residual disease status in adults with acute lymphoblastic leukemia treated with HyperCVAD. <i>American Journal of Hematology</i> , 2018, 93, 546-552.	2.0	13
65	Non-myeloablative allogeneic hematopoietic cell transplantation for relapsed or refractory Waldenström macroglobulinemia: evidence for a graft- versus -lymphoma effect. <i>Haematologica</i> , 2018, 103, e252-e255.	1.7	2
66	Reversal of Low Donor Chimerism after Hematopoietic Cell Transplantation Using Pentostatin and Donor Lymphocyte Infusion: A Prospective Phase II Multicenter Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 308-313.	2.0	6
67	Results of a phase I study of quizartinib as maintenance therapy in subjects with acute myeloid leukemia in remission following allogeneic hematopoietic stem cell transplant. <i>American Journal of Hematology</i> , 2018, 93, 222-231.	2.0	99
68	Hematopoietic Cell Transplantation for Myelofibrosis: the Dynamic International Prognostic Scoring System Plus Risk Predicts Post-Transplant Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 386-392.	2.0	52
69	Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 726-733.	2.0	71
70	cGMP production of astatine-211-labeled anti-CD45 antibodies for use in allogeneic hematopoietic cell transplantation for treatment of advanced hematopoietic malignancies. <i>PLoS ONE</i> , 2018, 13, e0205135.	1.1	26
71	Long-Term Follow-Up of 90Y-Ibritumomab Tiuxetan, Fludarabine, and Total Body Irradiation-Based Nonmyeloablative Allogeneic Transplant Conditioning for Persistent High-Risk B Cell Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2211-2215.	2.0	9
72	Safety and Efficacy of Yttrium-90-Labeled Anti-CD45 Antibody (90Y-DOTA-BC8) Followed By a Standard Reduced-Intensity Hematopoietic Stem Cell Transplant (HCT) Regimen for Patients with Refractory/Relapsed Leukemia or High-Risk Myelodysplastic Syndrome (MDS). <i>Blood</i> , 2018, 132, 1018-1018.	0.6	6

#	ARTICLE	IF	CITATIONS
73	Survival Differences Among Patients (pts) with Acute Myeloid Leukemia (AML) Treated with Allogeneic Hematopoietic Cell Transplantation (HCT) Versus Non-HCT Therapies: A Large Real-Time Multi-Center Prospective Longitudinal Observational Study. <i>Blood</i> , 2018, 132, 207-207.	0.6	2
74	The Alpha Emitter Astatine-211 Targeted to CD38 Can Eradicate Multiple Myeloma in Minimal Residual Disease Models. <i>Blood</i> , 2018, 132, 1941-1941.	0.6	2
75	Limitations to Receiving Allogeneic Hematopoietic Cell Transplantation for Treatment of Acute Myeloid Leukemia: A Large Multi-Center Prospective Longitudinal Observational Study. <i>Blood</i> , 2018, 132, 1388-1388.	0.6	0
76	Predictors of 90-Day Mortality after Admission to Intensive Care Unit (ICU) in Patients with Acute Myeloid Leukemia (AML): Application of a Novel, Recently Validated AML-Specific Risk Model. <i>Blood</i> , 2018, 132, 3986-3986.	0.6	0
77	Reduced Intensity Conditioning (RIC) Regimens Hematopoietic Cell Transplantation (HCT) for Acute Myeloid Leukemia (AML): A Comparison of Fludarabine/Busulfan (FB) and Fludarabine/Melphalan (FM) Based Regimens from the CIBMTR. <i>Blood</i> , 2018, 132, 3456-3456.	0.6	0
78	Pre-Transplant Monocytic Myeloid-Derived Suppressor Cell Frequency Has No Prognostic Role for Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in Remission. <i>Blood</i> , 2018, 132, 5255-5255.	0.6	0
79	Allogeneic transplantation for advanced acute myeloid leukemia: The value of complete remission. <i>Cancer</i> , 2017, 123, 2025-2034.	2.0	48
80	Cytogenetic risk determines outcomes after allogeneic transplantation in older patients with acute myeloid leukemia in their second complete remission: A Center for International Blood and Marrow Transplant Research cohort analysis. <i>Cancer</i> , 2017, 123, 2035-2042.	2.0	14
81	The cumulative burden of double-stranded DNA virus detection after allogeneic HCT is associated with increased mortality. <i>Blood</i> , 2017, 129, 2316-2325.	0.6	126
82	Comparing outcomes of matched related donor and matched unrelated donor hematopoietic cell transplants in adults with B-cell acute lymphoblastic leukemia. <i>Cancer</i> , 2017, 123, 3346-3355.	2.0	25
83	Outcomes of hematopoietic cell transplantation using donors or recipients with inherited chromosomally integrated HHV-6. <i>Blood</i> , 2017, 130, 1062-1069.	0.6	65
84	Allogeneic Hematopoietic Cell Transplantation Using Treosulfan-Based Conditioning for Treatment of Marrow Failure Disorders. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1669-1677.	2.0	45
85	Allogeneic Hematopoietic Cell Transplantation (HCT) in the Eighth Decade of Life: How Much Does Age Matter?. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, S98-S99.	2.0	2
86	EASIX in patients with acute graft-versus-host disease: a retrospective cohort analysis. <i>Lancet Haematology</i> , 2017, 4, e414-e423.	2.2	92
87	Hematopoietic Cell Transplantation in Myelodysplastic Syndromes after Treatment with Hypomethylating Agents. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1509-1514.	2.0	33
88	Reduced intensity conditioned allograft yields favorable survival for older adults with B-cell acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2017, 92, 42-49.	2.0	46
89	Allogeneic hematopoietic cell transplant for patients with end stage renal disease requiring dialysis – a single institution experience. <i>Leukemia and Lymphoma</i> , 2017, 58, 740-742.	0.6	6
90	A Phase I Trial of 90Y-BC8-DOTA (Anti-CD45) Monoclonal Antibody in Combination with Fludarabine and TBI As Conditioning for Allogeneic Peripheral Blood Stem Cell Transplant to Treat High Risk Multiple Myeloma. <i>Blood</i> , 2017, 130, 910-910.	0.6	5

#	ARTICLE	IF	CITATIONS
91	Tandem autologous/allogeneic hematopoietic cell transplantation with bortezomib maintenance therapy for high-risk myeloma. <i>Blood Advances</i> , 2017, 1, 2247-2256.	2.5	15
92	Comparison of Chronic Graft-Versus-Host Disease Severity and Functional Status after Cord Blood, Haploidentical Related and 1-Allele Mismatched Unrelated Donor Hematopoietic Cell Transplantation. <i>Blood</i> , 2017, 130, 73-73.	0.6	1
93	Total Body Irradiation (TBI) Dose Escalation Decreases Risk of Progression and Graft Rejection after Hematopoietic Cell Transplantation with Nonmyeloablative Conditioning for Myelodysplastic Syndrome (MDS) or Myeloproliferative Neoplasms (MPN). <i>Blood</i> , 2017, 130, 908-908.	0.6	1
94	Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis. <i>Cancer</i> , 2016, 122, 3005-3014.	2.0	45
95	Evaluation of allogeneic transplantation in first or later minimal residual disease "negative remission following adult-inspired therapy for acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2016, 57, 2109-2118.	0.6	28
96	Consistent Collection and Processing of Non-Mobilized Mononuclear Cell, Apheresis Products from HLA Haploidentical Bone Marrow Donors for Sequential CD3+ T-Cell Depletion and CD56+ NK Cell Enrichment. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S382-S383.	2.0	0
97	Association of Distance from Transplantation Center and Place of Residence on Outcomes after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1319-1323.	2.0	27
98	Nonmyeloablative allogeneic hematopoietic cell transplantation. <i>Haematologica</i> , 2016, 101, 521-530.	1.7	46
99	Minimal Identifiable Disease and the Role of Conditioning Intensity in Hematopoietic Cell Transplantation for Myelodysplastic Syndrome and Acute Myelogenous Leukemia Evolving from Myelodysplastic Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1227-1233.	2.0	36
100	Cord-Blood Transplantation in Patients with Minimal Residual Disease. <i>New England Journal of Medicine</i> , 2016, 375, 944-953.	13.9	352
101	Anti-CD45 radioimmunotherapy without TBI before transplantation facilitates persistent haploidentical donor engraftment. <i>Blood</i> , 2016, 127, 352-359.	0.6	29
102	Allogeneic Hematopoietic Cell Transplantation for Patients with Mixed Phenotype Acute Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1024-1029.	2.0	39
103	Steroids Versus Steroids Plus Additional Agent in Frontline Treatment of Acute Graft-versus-Host Disease: A Systematic Review and Meta-Analysis of Randomized Trials. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1133-1137.	2.0	25
104	Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study. <i>Lancet Haematology</i> , 2016, 3, e119-e127.	2.2	307
105	Prophylactic Natural Killer Cell Immunotherapy Following HLA-Haploidentical Hematopoietic Cell Transplantation Prevents Relapse and Improves Survival in Patients with High-Risk Hematological Malignancies. <i>Blood</i> , 2016, 128, 1161-1161.	0.6	3
106	Intensive Versus Non-Intensive Induction Therapy for Patients (Pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) Using Two Different Novel Prognostic Models. <i>Blood</i> , 2016, 128, 216-216.	0.6	18
107	Sirolimus Combined with Mycophenolate Mofetil (MMF) and Cyclosporine (CSP) Significantly Improves Prevention of Acute Graft-Versus-Host-Disease (GVHD) after Unrelated Hematopoietic Cell Transplantation (HCT): Results from a Phase III Randomized Multi-Center Trial. <i>Blood</i> , 2016, 128, 506-506.	0.6	3
108	It Is Easy to Predict Non-Relapse Mortality (NRM) of Allogeneic Stem Cell Transplantation (alloSCT). <i>Blood</i> , 2016, 128, 519-519.	0.6	19

#	ARTICLE	IF	CITATIONS
109	Comparison of Total Body Irradiation-Based with Intravenous Busulfan-Based Chemotherapy-Only Conditioning Regimens for Myeloablative Hematopoietic Cell Transplantation (HCT) in Adults with Acute Lymphoblastic Leukemia. <i>Blood</i> , 2016, 128, 679-679.	0.6	3
110	Consolidation Chemotherapy Is Not Beneficial for Adult Acute Lymphoblastic Leukemia Patients with Available Donor Undergoing Myeloablative Allogeneic Hematopoietic Cell Transplantation in First Complete Remission: A CIBMTR Study. <i>Blood</i> , 2016, 128, 684-684.	0.6	0
111	Reversal of Low Donor Chimerism Following Hematopoietic Cell Transplantation Using Pentostatin and Donor Lymphocyte Infusion. <i>Blood</i> , 2016, 128, 2215-2215.	0.6	0
112	Addition of Astatine-211-Labeled Anti-CD45 Antibody to Total Body Irradiation (TBI) As Conditioning for DLA-Identical Marrow Transplantation: A Novel Strategy to Overcome Graft Rejection in a Canine Presensitization Model. <i>Blood</i> , 2016, 128, 2152-2152.	0.6	1
113	Astatine-211 conjugated to an anti-CD20 monoclonal antibody eradicates disseminated B-cell lymphoma in a mouse model. <i>Blood</i> , 2015, 125, 2111-2119.	0.6	52
114	Quantitative single-particle digital autoradiography with $\alpha$ -particle emitters for targeted radionuclide therapy using the iQID camera. <i>Medical Physics</i> , 2015, 42, 4094-4105.	1.6	48
115	Multi-centre validation of the prognostic value of the haematopoietic cell transplantation-specific comorbidity index among recipient of allogeneic haematopoietic cell transplantation. <i>British Journal of Haematology</i> , 2015, 170, 574-583.	1.2	45
116	Long-term sustained disease control in patients with mantle cell lymphoma with or without active disease after treatment with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. <i>Cancer</i> , 2015, 121, 3709-3716.	2.0	27
117	Pre-transplant comorbidity burden and post-transplant chronic graft-versus-host disease. <i>British Journal of Haematology</i> , 2015, 171, 411-416.	1.2	9
118	Association of fludarabine pharmacokinetic/dynamic biomarkers with donor chimerism in nonmyeloablative HCT recipients. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 85-96.	1.1	14
119	$^{211}\text{At}$ -Imaging Confirmed Efficient Targeting of CD45-Positive Cells After $^{211}\text{At}$ -Radioimmunotherapy for Hematopoietic Cell Transplantation. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1766-1773.	2.8	18
120	Long-Term Outcomes of Patients with Advanced Mantle Cell Lymphoma Treated with Allogeneic Hematopoietic Cell Transplantation after Nonmyeloablative Conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S88-S89.	2.0	0
121	Allogeneic Hematopoietic Cell Transplantation (HCT) Yields Lower Relapse Rates but No Overall Survival Benefit for Adults with Acute Lymphoblastic Leukemia (ALL) in First Minimal Residual Disease (MRD)-Negative Remission. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S80-S81.	2.0	0
122	Number of Courses of Induction Therapy Independently Predicts Outcome after Allogeneic Transplantation for Acute Myeloid Leukemia in First Morphological Remission. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 373-378.	2.0	30
123	In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. <i>Mayo Clinic Proceedings</i> , 2015, 90, 996-1000.	1.4	128
124	$^{211}\text{At}$ -Conjugated Monoclonal CD45 Antibody-Based Nonmyeloablative Conditioning for Stem Cell Gene Therapy. <i>Human Gene Therapy</i> , 2015, 26, 399-406.	1.4	16
125	Effect of allogeneic hematopoietic cell transplantation in first complete remission on post-relapse complete remission rate and survival in acute myeloid leukemia. <i>Haematologica</i> , 2015, 100, e254-e256.	1.7	3
126	Design and Validation of an Augmented Hematopoietic Cell Transplantation-Comorbidity Index Comprising Pretransplant Ferritin, Albumin, and Platelet Count for Prediction of Outcomes after Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1418-1424.	2.0	62



#	ARTICLE	IF	CITATIONS
127	Population pharmacokinetic/dynamic model of lymphosuppression after fludarabine administration. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 75, 67-75.	1.1	13
128	Long-Term Outcomes of Patients with Persistent Indolent B-Cell Malignancies Undergoing Nonmyeloablative Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 281-287.	2.0	19
129	Urinary Elafin and Kidney Injury in Hematopoietic Cell Transplant Recipients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 12-20.	2.2	28
130	Impact of Donor Age on Outcome after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 105-112.	2.0	47
131	Comparison of Post-Allogeneic Hematopoietic Cell Transplantation (HCT) Outcomes after Matched Related Donor Versus Matched Unrelated Donor HCT in Adults with Acute Lymphoblastic Leukemia. <i>Blood</i> , 2015, 126, 2017-2017.	0.6	2
132	Analysis of Pre-Transplant Therapy with Brentuximab Vedotin for Relapsed/Refractory Hodgkin Lymphoma on Outcomes of Reduced Intensity Conditioned Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2015, 126, 4406-4406.	0.6	2
133	Time to Minimal Residual Disease (MRD) Negativity Is Independently Predictive of Outcome in Adults with Acute Lymphoblastic Leukemia (ALL) Receiving Hyper-CVAD. <i>Blood</i> , 2015, 126, 2498-2498.	0.6	0
134	Outcomes of Allogeneic Transplantation in Patients Aged $\geq$ 60 Years with Acute Myeloid Leukemia in Second Complete Remission: A CIBMTR $\text{\textcircled{R}}$ Cohort Analysis. <i>Blood</i> , 2015, 126, 2009-2009.	0.6	0
135	A Prospective Multicenter Study of Nonmyeloablative Conditioning with TBI or Fludarabine/TBI for HLA-Matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies with Post Grafting Immunosuppression with Tacrolimus and Mycophenolate Mofetil: 10-Year Experience. <i>Blood</i> , 2015, 126, 1949-1949.	0.6	1
136	A Novel Bispecific CD38 Antibody Eradicates Multiple Myeloma in a Mouse Model Following Yttrium-90-DOTA Capture. <i>Blood</i> , 2015, 126, 118-118.	0.6	1
137	Post-Hematopoietic Stem Cell Transplantation Minimal Residual Disease and Early Relapses in MDS and AML Evolving from MDS. <i>Blood</i> , 2015, 126, 2019-2019.	0.6	0
138	Failure-free survival after initial systemic treatment of chronic graft-versus-host disease. <i>Blood</i> , 2014, 124, 1363-1371.	0.6	86
139	Conditioning regimens for hematopoietic cell transplantation: one size does not fit all. <i>Blood</i> , 2014, 124, 344-353.	0.6	437
140	Treosulfan, Fludarabine, and 2-Gy Total Body Irradiation Followed by Allogeneic Hematopoietic Cell Transplantation in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 549-555.	2.0	47
141	Comorbidity-Age Index: A Clinical Measure of Biologic Age Before Allogeneic Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2014, 32, 3249-3256.	0.8	361
142	Costs of Allogeneic Hematopoietic Cell Transplantation Using Reduced Intensity Conditioning Regimens. <i>Oncologist</i> , 2014, 19, 639-644.	1.9	36
143	Central Nervous System Relapse in Adults with Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Stem-Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1767-1771.	2.0	46
144	Radioimmunotherapy-Augmented Nonmyeloablative Allogeneic Transplantation Improves Outcomes for Refractory Indolent B-Cell Non-Hodgkin Lymphoma: Results of an Adjusted Cohort Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, S72-S73.	2.0	0

#	ARTICLE	IF	CITATIONS
145	Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant in Patients with End Stage Renal Disease Requiring Dialysis – a Single Institution Experience. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, S251.	2.0	2
146	Pharmacokinetic and Pharmacodynamic Analysis of Inosine Monophosphate Dehydrogenase Activity in Hematopoietic Cell Transplantation Recipients Treated with Mycophenolate Mofetil. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1121-1129.	2.0	21
147	Radiolabeled Anti-CD45 Antibody with Reduced-Intensity Conditioning and Allogeneic Transplantation for Younger Patients with Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1363-1368.	2.0	54
148	Recipient Pretransplant Inosine Monophosphate Dehydrogenase Activity in Nonmyeloablative Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1544-1552.	2.0	7
149	A randomized phase II trial of tacrolimus, mycophenolate mofetil and sirolimus after non-myeloablative unrelated donor transplantation. <i>Haematologica</i> , 2014, 99, 1624-1631.	1.7	33
150	Pretransplant comorbidities predict severity of acute graft-versus-host disease and subsequent mortality. <i>Blood</i> , 2014, 124, 287-295.	0.6	83
151	Role of Comorbidities in Prognostic Evaluation of Outcomes Following Allogeneic Hematopoietic Cell Transplantation (HCT) from HLA-Mismatched (MM) and Umbilical Cord Blood (UCB) Donor Grafts. <i>Blood</i> , 2014, 124, 2583-2583.	0.6	3
152	Superiority of Pediatric Chemotherapy over Allogeneic Hematopoietic Cell Transplantation for Philadelphia Chromosome Negative Adult ALL in First Complete Remission: A Combined Analysis of Dana-Farber ALL Consortium and CIBMTR Cohorts. <i>Blood</i> , 2014, 124, 319-319.	0.6	6
153	FLT3 Mutation Increases Relapse Risk after Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia in First or Second Complete Remission: A Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis. <i>Blood</i> , 2014, 124, 322-322.	0.6	4
154	Results of a Phase I Study of Quizartinib (AC220) As Maintenance Therapy in Subjects with Acute Myeloid Leukemia in Remission Following Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2014, 124, 428-428.	0.6	29
155	Pre-Transplant Ferritin, Albumin and Platelet Count Add Prognostic Information to Comorbidities for Allogeneic Hematopoietic Cell Transplantation (HCT) Outcomes: A Multi-Center Discovery-Validation Study. <i>Blood</i> , 2014, 124, 421-421.	0.6	1
156	Effect of Allogeneic Hematopoietic Cell Transplant in First Complete Remission on Post-Relapse CR Rate and Survival in Acute Myeloid Leukemia. <i>Blood</i> , 2014, 124, 5257-5257.	0.6	0
157	211At-Anti-CD45 Radioimmunotherapy Can Replace TBI Prior to Haploidentical Bone Marrow Transplantation and Yield Long-Term Hematopoietic Engraftment. <i>Blood</i> , 2014, 124, 2417-2417.	0.6	0
158	A pilot pharmacologic biomarker study in HLA-haploidentical hematopoietic cell transplant recipients. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 72, 607-618.	1.1	9
159	Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial CD3+ T Cell Dose. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 949-957.	2.0	79
160	Frequency of Allogeneic Hematopoietic Cell Transplantation Among Patients With High- or Intermediate-Risk Acute Myeloid Leukemia in First Complete Remission. <i>Journal of Clinical Oncology</i> , 2013, 31, 3883-3888.	0.8	42
161	Fludarabine and 2-Gy TBI is Superior to 2ÂGy TBI as Conditioning for HLA-Matched Related Hematopoietic Cell Transplantation: A Phase III Randomized Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1340-1347.	2.0	23
162	Allogeneic Hematopoietic Cell Transplantation following Minimal Intensity Conditioning: Predicting Acute Graft-versus-Host Disease and Graft-versus-Tumor Effects. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 792-798.	2.0	27

#	ARTICLE	IF	CITATIONS
163	Nonrelapse Mortality and Mycophenolic Acid Exposure in Nonmyeloablative Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1159-1166.	2.0	29
164	Allogeneic hematopoietic cell transplantation for indolent non-Hodgkin lymphoma. <i>Current Opinion in Hematology</i> , 2013, 20, 509-514.	1.2	7
165	Graft-Versus-Host Disease and Graft-Versus-Tumor Effects After Allogeneic Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2013, 31, 1530-1538.	0.8	197
166	Safety of treatment with DLA-identical or unrelated mesenchymal stromal cells in DLA-identical canine bone marrow transplantation. <i>Chimerism</i> , 2013, 4, 95-101.	0.7	8
167	Incidence, risk factors, and outcomes of sclerosis in patients with chronic graft-versus-host disease. <i>Blood</i> , 2013, 121, 5098-5103.	0.6	93
168	Failure-free survival after second-line systemic treatment of chronic graft-versus-host disease. <i>Blood</i> , 2013, 121, 2340-2346.	0.6	55
169	Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission. <i>Blood</i> , 2013, 122, 1813-1821.	0.6	325
170	Costs of Second Allogeneic Hematopoietic Cell Transplantation. <i>Transplantation</i> , 2013, 96, 108-115.	0.5	7
171	High prevalence of potential drug interactions affecting mycophenolic acid pharmacokinetics in nonmyeloablative hematopoietic stem cell transplant recipients. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2013, 51, 711-7.	0.3	13
172	Anti-CD45 Monoclonal Antibody (MAb) Dose Optimization For Astatine-211 (211At)-Radioimmunotherapy (RIT) Of Relapsed Non-Hodgkin Lymphoma (NHL) In a Canine Model. <i>Blood</i> , 2013, 122, 5139-5139.	0.6	0
173	The Effect Of Donor and Recipient Statin Treatment On Infections After Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2013, 122, 4548-4548.	0.6	0
174	Modulated Cyclophosphamide-Based In Vivo T-Cell Depletion Promotes Engraftment With Minimal Gvhd and Low Toxicity In Fanconi Anemia Patients. <i>Blood</i> , 2013, 122, 4561-4561.	0.6	0
175	Failure-Free Survival After Initial Systemic Treatment Of Chronic GVHD. <i>Blood</i> , 2013, 122, 2053-2053.	0.6	0
176	Comparison Of Minimal Residual Disease As Outcome Predictor For AML Patients In First Complete Remission Undergoing Myeloablative Or Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2013, 122, 1317-1317.	0.6	0
177	Conditioning with $\beta$ -emitter based radioimmunotherapy in canine allogeneic hematopoietic cell transplantation. <i>Chimerism</i> , 2012, 3, 40-42.	0.7	3
178	A Limited Sampling Schedule to Estimate Mycophenolic Acid Area Under the Concentration-Time Curve in Hematopoietic Cell Transplantation Recipients. <i>Journal of Clinical Pharmacology</i> , 2012, 52, 1654-1664.	1.0	17
179	The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation. <i>Blood</i> , 2012, 119, 2657-2664.	0.6	133
180	Durable donor engraftment after radioimmunotherapy using $\beta$ -emitter astatine-211 labeled anti-CD45 antibody for conditioning in allogeneic hematopoietic cell transplantation. <i>Blood</i> , 2012, 119, 1130-1138.	0.6	52

#	ARTICLE	IF	CITATIONS
181	Reagents for Astatination of Biomolecules. 6. An Intact Antibody Conjugated with a Maleimido-<i>closo</i>-Decaborate(2-) Reagent via Sulfhydryl Groups Had Considerably Higher Kidney Concentrations than the Same Antibody Conjugated with an Isothiocyanato-<i>closo</i>-Decaborate(2-) Reagent via Lysine Amines. <i>Bioconjugate Chemistry</i> , 2012, 23, 409-420.	1.8	62
182	Association between Calcineurin Inhibitor Blood Concentrations and Outcomes after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 414-422.	2.0	42
183	Efficacy of a Viral Load-Based, Risk-Adapted, Preemptive Treatment Strategy for Prevention of Cytomegalovirus Disease after Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1687-1699.	2.0	145
184	Prognostic impact of discordant results from cytogenetics and flow cytometry in patients with acute myeloid leukemia undergoing hematopoietic cell transplantation. <i>Cancer</i> , 2012, 118, 2411-2419.	2.0	27
185	Hematopoietic Bone Marrow Transplantation (BMT) for Patients with High-Risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS) Using HLA-Haploidentical Related Donors: A Trial Using Radiolabeled Anti-CD45 Antibody Combined with Immunosuppression Before and After BMT. <i>Blood</i> , 2012, 120, 4164-4164.	0.6	3
186	Second Allogeneic Hematopoietic Cell Transplantation in Patients with Hematologic Malignancies for Relapse After First Allografts. <i>Blood</i> , 2012, 120, 4207-4207.	0.6	1
187	Quantitative Significance of Minimal Residual Disease Before Myeloablative Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in First and Second Complete Remission. <i>Blood</i> , 2012, 120, 655-655.	0.6	0
188	A Phase II Trial Combining Radiolabeled Anti-CD45 Antibody with Fludarabine and Low-Dose Total Body Irradiation (TBI) Followed by Related or Unrelated Hematopoietic Cell Transplantation for Patients Under Age 50 with Advanced Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS). <i>Blood</i> , 2012, 120, 1924-1924.	0.6	0
189	Donor Lymphocyte Infusion for Relapsed Hematological Malignancies After Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial CD3+ T Cell Dose. <i>Blood</i> , 2012, 120, 354-354.	0.6	0
190	Allogeneic hematopoietic cell transplantation for renal cell carcinoma: ten years after. <i>Expert Opinion on Biological Therapy</i> , 2011, 11, 763-773.	1.4	8
191	Immunomodulatory effects induced by cytotoxic T lymphocyte antigen 4 immunoglobulin with donor peripheral blood mononuclear cell infusion in canine major histocompatibility complexâ€“haplo-identical non-myeloablative hematopoietic cell transplantation. <i>Cytotherapy</i> , 2011, 13, 1269-1280.	0.3	17
192	Allogeneic Hematopoietic Cell Transplantation for Chronic Myelomonocytic Leukemia: Relapse-Free Survival Is Determined by Karyotype and Comorbidities. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 908-915.	2.0	113
193	A Phase I/II Study of Chemotherapy Followed by Donor Lymphocyte Infusion plus Interleukin-2 for Relapsed Acute Leukemia after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1308-1315.	2.0	17
194	Histology and Time to Progression Predict Survival for Lymphoma Recurring after Reduced-Intensity Conditioning and Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1537-1545.	2.0	30
195	Decreased Serum Albumin as a Biomarker for Severe Acute Graft-versus-Host Disease after Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1594-1601.	2.0	60
196	Thymic recovery after allogeneic hematopoietic cell transplantation with non-myeloablative conditioning is limited to patients younger than 60 years of age. <i>Haematologica</i> , 2011, 96, 298-306.	1.7	71
197	Cytopenias after day 28 in allogeneic hematopoietic cell transplantation: impact of recipient/donor factors, transplant conditions and myelotoxic drugs. <i>Haematologica</i> , 2011, 96, 1838-1845.	1.7	47
198	Allogeneic haematopoietic cell transplantation for myelofibrosis in 30 patients 60â€“78â€“years of age. <i>British Journal of Haematology</i> , 2011, 153, 76-82.	1.2	51

#	ARTICLE	IF	CITATIONS
199	Long-term Outcomes Among Older Patients Following Nonmyeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation for Advanced Hematologic Malignancies. <i>JAMA - Journal of the American Medical Association</i> , 2011, 306, 1874.	3.8	274
200	Non-myeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high-risk acute lymphoblastic leukemia. <i>Haematologica</i> , 2011, 96, 1113-1120.	1.7	95
201	Multi-Institutional Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) for HCT Outcomes. <i>Blood</i> , 2011, 118, 145-145.	0.6	4
202	Impact of Pre-Transplant Comorbidities on the Rate of- and Mortality-Following Acute Graft-Versus-Host Disease (GVHD) After Allogeneic Hematopoietic Cell Transplantation (HCT). <i>Blood</i> , 2011, 118, 156-156.	0.6	33
203	Interaction of Age and Comorbidities and Their Impacts on Hematopoietic Cell Transplantation (HCT) Outcomes. <i>Blood</i> , 2011, 118, 665-665.	0.6	2
204	Umbilical Cord Blood Transplantation in Patients with Hematological Malignancies Using a Non-ATG Containing Reduced Intensity Preparative Regimen. <i>Blood</i> , 2011, 118, 1943-1943.	0.6	3
205	Peripheral Blood Stem Cell Mobilization with Single Agent Plerixafor Induces FoxP3 Expression in Donor T Cells and Enables Durable Long Term Hematopoietic Engraftment Across Mismatched Major Histocompatibility Complex Barriers. <i>Blood</i> , 2011, 118, 1891-1891.	0.6	0
206	Impact of Comorbidities on Early and Late Mortalities After Allogeneic Hematopoietic Cell Transplantation (HCT). <i>Blood</i> , 2011, 118, 326-326.	0.6	1
207	Incidence, Risk Factors and Outcomes of Sclerotic Chronic Graft-Versus-Host Disease (GVHD) Phenotype After Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2011, 118, 322-322.	0.6	0
208	Pilot Study of a 213Bismuth-Labeled Anti-CD45 mAb as a Novel Nonmyeloablative Conditioning for DLA-Haploidentical Littermate Hematopoietic Transplantation. <i>Transplantation</i> , 2010, 89, 1336-1340.	0.5	14
209	Plerixafor-mobilized stem cells alone are capable of inducing early engraftment across the MHC-haploidentical canine barrier. <i>Blood</i> , 2010, 115, 916-917.	0.6	7
210	Who is fit for allogeneic transplantation?. <i>Blood</i> , 2010, 116, 4762-4770.	0.6	93
211	Donor statin treatment protects against severe acute graft-versus-host disease after related allogeneic hematopoietic cell transplantation. <i>Blood</i> , 2010, 115, 1288-1295.	0.6	50
212	The impact of donor type and ABO incompatibility on transfusion requirements after nonmyeloablative haematopoietic cell transplantation. <i>British Journal of Haematology</i> , 2010, 149, 101-110.	1.2	46
213	Allogeneic haematopoietic cell transplantation after nonmyeloablative conditioning in patients with Tâ€cell and natural killerâ€cell lymphomas. <i>British Journal of Haematology</i> , 2010, 150, 170-178.	1.2	44
214	Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2010, 28, 2859-2867.	0.8	191
215	Optimizing reduced-intensity conditioning regimens for myeloproliferative neoplasms. <i>Expert Review of Hematology</i> , 2010, 3, 23-33.	1.0	3
216	Low-Dose Total Body Irradiation and Fludarabine Conditioning for HLA Class I-Mismatched Donor Stem Cell Transplantation and Immunologic Recovery in Patients with Hematologic Malignancies: A Multicenter Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 384-394.	2.0	39

#	ARTICLE	IF	CITATIONS
217	Outcome of Allogeneic Hematopoietic Cell Transplantation from HLA-Identical Siblings for Severe Aplastic Anemia in Patients Over 40 Years of Age. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 1411-1418.	2.0	41
218	Impact of Recipient Statin Treatment on Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 1463-1466.	2.0	40
219	Reduced Mortality after Allogeneic Hematopoietic-Cell Transplantation. <i>New England Journal of Medicine</i> , 2010, 363, 2091-2101.	13.9	1,335
220	Impacts of Cytogenetic Abnormalities and Prior Alemtuzumab on Outcomes of Patients (pts) with High-Risk Chronic Lymphocytic Leukemia (CLL) Given Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT). <i>Blood</i> , 2010, 116, 2364-2364.	0.6	2
221	International Working Group Scores Predict Post-Transplant Outcomes In Patients with Myelofibrosis. <i>Blood</i> , 2010, 116, 3085-3085.	0.6	5
222	A Relapse Risk Score to Predict Acute Myeloid Leukemia Relapse After Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation Based on Pre-Transplant Variables.. <i>Blood</i> , 2010, 116, 3450-3450.	0.6	1
223	Effect of Peripheral Blood Stem Cell (PBSC) Graft Composition on Graft Versus Host Disease (GVHD) and Mortality After Allogeneic Transplantation. <i>Blood</i> , 2010, 116, 676-676.	0.6	2
224	Donor Engraftment Following $\beta$ -Emitter Astatine-211 ( $^{211}\text{At}$ ) Labeled Anti-CD45 Monoclonal Antibody (mAb) Nonmyeloablative Conditioning for Dog Leukocyte Antigen (DLA)-Identical Marrow Transplantation. <i>Blood</i> , 2010, 116, 76-76.	0.6	0
225	Treatment of Recurrent or Persistent AML/MDS After Allogeneic Hematopoietic Cell Transplantation with Azacitidine.. <i>Blood</i> , 2010, 116, 1288-1288.	0.6	2
226	Outcomes Following Relapse of Non-Hodgkin Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL) After Nonmyeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation (HCT) From HLA-Matched Related or Unrelated Donors. <i>Blood</i> , 2010, 116, 1292-1292.	0.6	0
227	Concordance of CNS Leukemia Detection Between Morphology and Flow Cytometry Prior to Stem Cell Transplantation In Patients with MDS, AML, ALL and CMML. <i>Blood</i> , 2010, 116, 4842-4842.	0.6	0
228	Sequential Autologous Followed by Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT) From HLA-Matched Related or Unrelated Donors Improves Outcomes of Patients (pts) with Bulky Lymphoma or Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2010, 116, 2365-2365.	0.6	5
229	Timing and severity of community acquired respiratory virus infections after myeloablative versus non-myeloablative hematopoietic stem cell transplantation. <i>Haematologica</i> , 2009, 94, 1101-1108.	1.7	86
230	Biodistributions, Myelosuppression, and Toxicities in Mice Treated with an Anti-CD45 Antibody Labeled with the $\beta$ -Emitting Radionuclides Bismuth-213 or Astatine-211. <i>Cancer Research</i> , 2009, 69, 2408-2415.	0.4	47
231	A Limited Sampling Schedule to Estimate Individual Pharmacokinetic Parameters of Fludarabine in Hematopoietic Cell Transplant Patients. <i>Clinical Cancer Research</i> , 2009, 15, 5280-5287.	3.2	22
232	Transmission and expansion of HOXB4-induced leukemia in two immunosuppressed dogs: Implications for a new canine leukemia model. <i>Experimental Hematology</i> , 2009, 37, 1157-1166.	0.2	9
233	A novel phenotypic method to determine fludarabine triphosphate accumulation in T-lymphocytes from hematopoietic cell transplantation patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 63, 391-401.	1.1	19
234	Intracellular disposition of fludarabine triphosphate in human natural killer cells. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 63, 959-964.	1.1	7

#	ARTICLE	IF	CITATIONS
235	Reagents for Astatination of Biomolecules. 4. Comparison of Maleimido-<i>closo</i>-Decaborate(2-) and <i>meta</i>-[ <sup>211</sup> At]Astatobenzoate Conjugates for Labeling anti-CD45 Antibodies with [ <sup>211</sup> At]Astatine. <i>Bioconjugate Chemistry</i> , 2009, 20, 1983-1991.	1.8	27
236	What Is the Role for Donor Natural Killer Cells after Nonmyeloablative Conditioning?. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 580-588.	2.0	52
237	Effect of Conditioning Regimen Intensity on CMV Infection in Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 694-703.	2.0	70
238	Delaying DLA-Haploidentical Hematopoietic Cell Transplantation after Total Body Irradiation. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 1244-1250.	2.0	11
239	Salvage Allogeneic Hematopoietic Cell Transplantation with Fludarabine and Low-Dose Total Body Irradiation after Rejection of First Allografts. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 1314-1322.	2.0	29
240	Defining the Intensity of Conditioning Regimens: Working Definitions. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 1628-1633.	2.0	1,419
241	Allogeneic hematopoietic cell transplantation after conditioning with <sup>131</sup> I anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome. <i>Blood</i> , 2009, 114, 5444-5453.	0.6	161
242	Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting. <i>Blood</i> , 2009, 113, 3383-3391.	0.6	106
243	A Randomized 3-Arm Phase II Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute Graft-Versus-Host Disease (GVHD) After Unrelated Donor Hematopoietic Cell Transplantation (HCT) Using Nonmyeloablative Conditioning for Patients with Hematologic Malignancies: A Multi-Center Trial.. <i>Blood</i> , 2009, 114, 348-348.	0.6	4
244	Low Albumin, High Ferritin, and Thrombocytopenia Before Transplant Predict Non-Relapse Mortality (NRM) Independent of the Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI).. <i>Blood</i> , 2009, 114, 651-651.	0.6	15
245	Reduced Intensity Conditioning with Allogeneic Hematopoietic Cell Transplantation for the Treatment of High-Risk Acute Lymphoblastic Leukemia.. <i>Blood</i> , 2009, 114, 1210-1210.	0.6	0
246	Outcomes of Early Relapse Following Non-Myeloablative Allogeneic Transplant for Lymphoma.. <i>Blood</i> , 2009, 114, 1204-1204.	0.6	1
247	Nonmyeloablative Allogeneic HCT From Unrelated Donors for Multiple Myeloma (MM).. <i>Blood</i> , 2009, 114, 3391-3391.	0.6	0
248	Falling Serum Albumin Predicts Severity of Acute Graft-Vs.-Host Disease and Non-Relapse Mortality After Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation.. <i>Blood</i> , 2009, 114, 1146-1146.	0.6	1
249	Frequency of Allogeneic Stem Cell Transplant(SCT) in Patients Presenting with Newly-Diagnosed AML or AML at Time of First Salvage Therapy.. <i>Blood</i> , 2009, 114, 4332-4332.	0.6	0
250	Thymic Recovery After Allogeneic Hematopoietic Cell Transplantation with Nonmyeloablative Conditioning Might Be Limited to Patients Younger Than 60 Years of Age.. <i>Blood</i> , 2009, 114, 1149-1149.	0.6	0
251	Hematopoietic cell transplantation comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation. <i>Cancer</i> , 2008, 112, 1992-2001.	2.0	233
252	Non myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B cell lymphoma: a multicentre experience. <i>British Journal of Haematology</i> , 2008, 143, 395-403.	1.2	97

#	ARTICLE	IF	CITATIONS
253	Reduced-Intensity Conditioning followed by Allogeneic Hematopoietic Cell Transplantation for Adult Patients with Myelodysplastic Syndrome and Myeloproliferative Disorders. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 246-255.	2.0	133
254	Impact of Acute Kidney Injury on Long-Term Mortality after Nonmyeloablative Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 309-315.	2.0	52
255	HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 641-650.	2.0	1,525
256	Comparison of Outcomes of HLA-Matched Related, Unrelated, or HLA-Haploidentical Related Hematopoietic Cell Transplantation following Nonmyeloablative Conditioning for Relapsed or Refractory Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 1279-1287.	2.0	251
257	Five-Year Follow-Up of Patients With Advanced Chronic Lymphocytic Leukemia Treated With Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning. <i>Journal of Clinical Oncology</i> , 2008, 26, 4912-4920.	0.8	257
258	Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation in Relapsed, Refractory, and Transformed Indolent Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2008, 26, 211-217.	0.8	186
259	<i>C19orf48</i> Encodes a Minor Histocompatibility Antigen Recognized by CD8+ Cytotoxic T Cells from Renal Cell Carcinoma Patients. <i>Clinical Cancer Research</i> , 2008, 14, 5260-5269.	3.2	59
260	Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia. <i>Blood</i> , 2008, 111, 446-452.	0.6	181
261	Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation in Patients with De Novo and Secondary Acute Myeloid Leukemia. <i>Blood</i> , 2008, 112, 149-149.	0.6	4
262	Sustained Graft-Versus-Lymphoma Effect among Patients (pts) with Mantle Cell Lymphoma (MCL) Given Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT).. <i>Blood</i> , 2008, 112, 2147-2147.	0.6	4
263	Allogeneic Hematopoietic Cell Transplantation (HCT) after Nonmyeloablative Conditioning for Patients (pts) Aged $\geq 60$ Years.. <i>Blood</i> , 2008, 112, 2162-2162.	0.6	2
264	Allogeneic Hematopoietic Cell Transplants in Patients with Myelofibrosis Age 60 and Older. <i>Blood</i> , 2008, 112, 2798-2798.	0.6	1
265	Tandem Auto/AlloHCT for Newly Diagnosed Multiple Myeloma (MM) Patients.. <i>Blood</i> , 2008, 112, 1130-1130.	0.6	0
266	Transfusion Requirements in Allogeneic Hematopoietic Cell Transplantation (HCT) Recipients Given Either Myeloablative or Nonmyeloablative Conditioning, and Effect of ABO Incompatibility on HCT Outcomes.. <i>Blood</i> , 2008, 112, 3268-3268.	0.6	0
267	Evaluation of Toxicity and Tissue Radiation Doses Obtained in Mice with An Anti-CD45 Monoclonal Antibody (mAb) Labeled with the Alpha-Emitting Radionuclides, Astatine-211 or Bismuth-213.. <i>Blood</i> , 2008, 112, 3270-3270.	0.6	0
268	Adult Cord Blood Transplantation (CBT) Vs. Unrelated Donor Transplantation: A Cost Comparison. <i>Blood</i> , 2008, 112, 2383-2383.	0.6	0
269	Salvage Allogeneic Hematopoietic Cell Transplantation with Fludarabine and Total Body Irradiation (3 Tj ETQq1 1 0,784314 rgBT /Over	0.6	0
270	Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. <i>Blood</i> , 2007, 110, 2744-2748.	0.6	156



#	ARTICLE	IF	CITATIONS
271	Hematopoietic cell transplantation-specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences. <i>Blood</i> , 2007, 110, 4606-4613.	0.6	292
272	Hematopoietic Cell Transplantation as Curative Therapy for Idiopathic Myelofibrosis, Advanced Polycythemia Vera, and Essential Thrombocythemia. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 355-365.	2.0	174
273	Nonmyeloablative Unrelated Donor Hematopoietic Cell Transplantation to Treat Patients with Poor-Risk, Relapsed, or Refractory Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 423-432.	2.0	40
274	Reduced-Intensity Conditioning for Unrelated Donor Progenitor Cell Transplantation: Long-Term Follow-Up of the First 285 Reported to the National Marrow Donor Program. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 844-852.	2.0	65
275	Extended Mycophenolate Mofetil and Shortened Cyclosporine Failed to Reduce Graft-versus-Host Disease after Unrelated Hematopoietic Cell Transplantation with Nonmyeloablative Conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 1041-1048.	2.0	19
276	Outcomes among Patients with Recurrent High-Risk Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 1160-1168.	2.0	110
277	Comparable Outcomes after Nonmyeloablative Hematopoietic Cell Transplantation with Unrelated and Related Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 1499-1507.	2.0	39
278	Comorbidity and Disease Status-Based Risk Stratification of Outcomes Among Patients With Acute Myeloid Leukemia or Myelodysplasia Receiving Allogeneic Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2007, 25, 4246-4254.	0.8	380
279	Comparison of Allogeneic Hematopoietic Cell Transplantation (HCT) after Nonmyeloablative Conditioning with HLA-Matched Related (MRD), Unrelated (URD), and Related Haploidentical (Haplo) Donors for Relapsed or Refractory Hodgkin Lymphoma (HL).. <i>Blood</i> , 2007, 110, 173-173.	0.6	5
280	What Is the Role for Donor NK Cells after Nonmyeloablative Conditioning?. <i>Blood</i> , 2007, 110, 476-476.	0.6	2
281	Higher Doses of Transplanted T and B Cells Are Associated with Greater Incidence of Extensive Chronic GVHD after PBSC Transplantation from HLA-Identical Sibling Donors.. <i>Blood</i> , 2007, 110, 1077-1077.	0.6	2
282	Reversal of Low Chimerism Following Nonmyeloablative (NM) Hematopoietic Cell Transplantation (HCT) Using Pentostatin and Donor Lymphocyte Infusions (DLI).. <i>Blood</i> , 2007, 110, 480-480.	0.6	0
283	Outcomes in the Recent Seattle Cord Blood Experience: Low TRM and Relapse; High Mild Acute GVHD and CMV Reactivation.. <i>Blood</i> , 2007, 110, 2019-2019.	0.6	0
284	Long-Term Outcome of Autologous Followed by Nonmyeloablative Allografting from HLA-Identical Sibling for Multiple Myeloma (MM).. <i>Blood</i> , 2007, 110, 3029-3029.	0.6	2
285	Long-Term Follow Up of Patients (pts) with High-Risk Chronic Lymphocytic Leukemia (CLL) Given Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT).. <i>Blood</i> , 2007, 110, 1662-1662.	0.6	1
286	Outcomes of Allogeneic Hematopoietic Cell Transplantation (HCT) after Non-Myeloablative Conditioning in Relapsed Diffuse Large B-Cell Lymphoma (DLBCL).. <i>Blood</i> , 2007, 110, 3037-3037.	0.6	0
287	Duration of Immunosuppressive Therapy for Chronic Graft-vs.-Host Disease (cGVHD) Following Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation (HCT).. <i>Blood</i> , 2007, 110, 1071-1071.	0.6	0
288	A Large Cohort Analysis of CMV Viral Load and Ganciclovir-Related Neutropenia in Nonmyeloablative (NM-HCT) and Myeloablative (M-HCT) Allogeneic Hematopoietic Cell Transplant Recipients.. <i>Blood</i> , 2007, 110, 2975-2975.	0.6	0

#	ARTICLE	IF	CITATIONS
289	Low-Dose Total Body Irradiation (TBI) and Fludarabine Conditioning for Hematopoietic Cell Transplantation (HCT) in Patients with HLA-Class I Mismatched Donors.. Blood, 2007, 110, 3067-3067.	0.6	0
290	Radioimmunotherapy as non-myeloablative conditioning for allogeneic marrow transplantation. Leukemia and Lymphoma, 2006, 47, 1205-1214.	0.6	19
291	Treatment for Acute Myelogenous Leukemia by Low-Dose, Total-Body, Irradiation-Based Conditioning and Hematopoietic Cell Transplantation From Related and Unrelated Donors. Journal of Clinical Oncology, 2006, 24, 444-453.	0.8	243
292	Unrelated Donor Granulocyte Colony-Stimulating Factorâ€œMobilized Peripheral Blood Mononuclear Cell Transplantation after Nonmyeloablative Conditioning: The Effect of Postgrafting Mycophenolate Mofetil Dosing. Biology of Blood and Marrow Transplantation, 2006, 12, 454-465.	2.0	83
293	Reduced Incidence of Acute and Chronic Graft-versus-Host Disease with the Addition of Thymoglobulin to a Targeted Busulfan/Cyclophosphamide Regimen. Biology of Blood and Marrow Transplantation, 2006, 12, 573-584.	2.0	88
294	Improving the Efficacy of Reduced Intensity Allogeneic Transplantation for Lymphoma using Radioimmunotherapy. Biology of Blood and Marrow Transplantation, 2006, 12, 697-702.	2.0	36
295	Failure of Donor Lymphocyte Infusion to Prevent Graft Rejection in Dogs Given DLA-Identical Marrow after 1 Gy of Total Body Irradiation. Biology of Blood and Marrow Transplantation, 2006, 12, 813-817.	2.0	9
296	Unrelated Donor Status and High Donor Age Independently Affect Immunologic Recovery after Nonmyeloablative Conditioning. Biology of Blood and Marrow Transplantation, 2006, 12, 1176-1187.	2.0	46
297	Extending Postgrafting Cyclosporine Decreases the Risk of Severe Graft-versus-Host Disease after Nonmyeloablative Hematopoietic Cell Transplantation. Transplantation, 2006, 81, 818-825.	0.5	38
298	Platelet and Red Blood Cell (RBC) Transfusion Requirements of Nonmyeloablative (NM) HLA-Matched Related and Unrelated Donor Hematopoietic Cell Transplantation (HCT): Influence of Genetic Disparity and ABO-Incompatibility.. Blood, 2006, 108, 2985-2985.	0.6	1
299	Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT) for Refractory Waldenstromâ€™s Macroglobulinemia (WM): Evidence for a Graft-Versus-WM Effect.. Blood, 2006, 108, 3034-3034.	0.6	4
300	A Phase II Trial of 90Y-Ibritumomab Tiuxetan-Based Reduced Intensity Allogeneic Peripheral Blood Stem Cell (PBSC) Transplantation for Relapsed CD20+ B-Cell Non-Hodgkins Lymphoma (NHL).. Blood, 2006, 108, 316-316.	0.6	10
301	Impacts of Comorbidities on Outcomes of Patients (pts) Diagnosed with B-Cell Malignancies and Treated with Allogeneic Hematopoietic Cell Transplantation (HCT) Using Nonmyeloablative (NM) vs Myeloablative (M) Conditioning.. Blood, 2006, 108, 550-550.	0.6	0
302	Outcomes of c Hematopoietic Stem Cell Transplantation (HCT) after Non-Myeloablative Conditioning in Relapsed, Refractory, or Transformed Indolent Non-Hodgkin Lymphoma (NHL).. Blood, 2006, 108, 3124-3124.	0.6	1
303	Favorable Outcome of Patients with Relapsed Hodgkin Lymphoma (HL) after Nonmyeloablative Hematopoietic Cell Transplantation (NM-HCT) Using Related Haploidentical Donors.. Blood, 2006, 108, 3135-3135.	0.6	9
304	Serious Acute or Chronic Graft-Versus-Host Disease after Hematopoietic Cell Transplantation: A Comparison of Myeloablative and Non-Myeloablative Conditioning Regimens.. Blood, 2006, 108, 755-755.	0.6	0
305	High-Dose Methotrexate (MTX) as Part of a Novel Immunosuppressive Regimen in Canine MHC-Haploidentical Hematopoietic Cell Transplantation (HCT).. Blood, 2006, 108, 3180-3180.	0.6	0
306	Outcomes among Patients with Recurrent High-Risk Hematologic Malignancy after Nonmyeloablative Versus Myeloablative Allogeneic Hematopoietic Cell Transplantation.. Blood, 2006, 108, 262-262.	0.6	7

#	ARTICLE	IF	CITATIONS
307	The Joint Role of Comorbidity and Performance Status (PS) in Predicting Morbidity after Allogeneic Nonmyeloablative Hematopoietic Cell Transplantation (HCT).. Blood, 2006, 108, 596-596.	0.6	1
308	Postgrafting Immunosuppression with Prolonged Mycophenolate Mofetil (MMF) and Truncated Cyclosporine (CSP) Failed To Reduce the Incidence of Graft-Versus-Host Disease (GVHD) after Unrelated Donor Hematopoietic Cell Transplantation (HCT) with Nonmyeloablative Conditioning.. Blood, 2006, 108, 3119-3119.	0.6	0
309	Prolonged Allogeneic Marrow Engraftment following Nonmyeloablative Conditioning Using 100 cGy Total Body Irradiation and Pentostatin before and Pharmacological Immunosuppression after Transplantation. Transplantation, 2005, 80, 1518-1521.	0.5	7
310	Current status of hematopoietic stem cell transplantation after nonmyeloablative conditioning. Current Opinion in Hematology, 2005, 12, 435-443.	1.2	34
311	Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood, 2005, 106, 2912-2919.	0.6	2,427
312	Prognostic relevance of 'early-onset' graft-versus-host disease following non-myeloablative haematopoietic cell transplantation. British Journal of Haematology, 2005, 129, 381-391.	1.2	41
313	Comparison of ARF after myeloablative and nonmyeloablative hematopoietic cell transplantation. American Journal of Kidney Diseases, 2005, 45, 502-509.	2.1	99
314	Graft-Versus-Tumor Effects After Allogeneic Hematopoietic Cell Transplantation With Nonmyeloablative Conditioning. Journal of Clinical Oncology, 2005, 23, 1993-2003.	0.8	312
315	Targeted Cancer Therapy Using Radiolabeled Monoclonal Antibodies. Technology in Cancer Research and Treatment, 2005, 4, 393-405.	0.8	16
316	Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning for Advanced Chronic Lymphocytic Leukemia. Journal of Clinical Oncology, 2005, 23, 3819-3829.	0.8	214
317	HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with chronic myeloid leukemia. Biology of Blood and Marrow Transplantation, 2005, 11, 272-279.	2.0	48
318	Comparison of lung function after myeloablative and 2 Gy of total body irradiation-based regimens for hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation, 2005, 11, 288-296.	2.0	43
319	Feasibility of Allogeneic Hematopoietic Stem Cell Transplantation for Autoimmune Disease: Position Statement from a National Institute of Allergy and Infectious Diseases and National Cancer Instituteâ€“Sponsored International Workshop, Bethesda, MD, March 12 and 13, 2005. Biology of Blood and Marrow Transplantation, 2005, 11, 862-870.	2.0	56
320	Allogeneic Hematopoietic Cell Transplantation (HCT) after Nonmyeloablative Conditioning for Relapsed or Refractory Follicular Lymphoma.. Blood, 2005, 106, 1130-1130.	0.6	25
321	131I-Anti-CD45 Antibody Plus Fludarabine, Low-Dose Total Body Irradiation and Peripheral Blood Stem Cell Infusion for Elderly Patients with Advanced Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS).. Blood, 2005, 106, 397-397.	0.6	19
322	Nonmyeloablative and Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies: Outcomes with HLA-Matched Unrelated Donors Compared to HLA-Identical Sibling Donors.. Blood, 2005, 106, 658-658.	0.6	10
323	Relationship between Conditioning Intensity and Comorbidity in Patients (Pts) with Acute Myeloid Leukemia (AML) or Myelodysplasia (MDS) Receiving Allogeneic Hematopoietic Cell Transplantation (HCT).. Blood, 2005, 106, 705-705.	0.6	2
324	A Polymorphic Oncofetal Antigen Recognized by CD8+ CTL from Two Patients Experiencing Regression of Metastatic Renal Cell Carcinoma after Allogeneic HCT.. Blood, 2005, 106, 3097-3097.	0.6	25

#	ARTICLE	IF	CITATIONS
325	Relapse Risk after Nonmyeloablative Hematopoietic Cell Transplantation for Malignant Diseases.. Blood, 2005, 106, 703-703.	0.6	1
326	Nonmyeloablative Unrelated Donor (URD) Hematopoietic Cell Transplantation (HCT) for the Treatment of Patients (pts) with Poor-Risk, Relapsed or Refractory Multiple Myeloma.. Blood, 2005, 106, 2893-2893.	0.6	1
327	DLA-Haploidentical Stem Cell Allografts after Anti-CD44 Therapy and Nonmyeloablative Conditioning: The Impact of Donor Lymphocyte Infusion (DLI), Pentostatin and Graft Composition on Donor Chimerism and Rejection.. Blood, 2005, 106, 2194-2194.	0.6	0
328	Allogeneic Hematopoietic Cell Transplantation for Metastatic Renal Cell Carcinoma after Nonmyeloablative Conditioning. Clinical Cancer Research, 2004, 10, 7799-7811.	3.2	89
329	Acute Renal Failure after Nonmyeloablative Hematopoietic Cell Transplantation. Journal of the American Society of Nephrology: JASN, 2004, 15, 1868-1876.	3.0	84
330	Vaccination as a treatment for breast or ovarian cancer. Expert Review of Vaccines, 2004, 3, 269-277.	2.0	8
331	Vaccination with Theratope® (STn-KLH) as treatment for breast cancer. Expert Review of Vaccines, 2004, 3, 655-663.	2.0	118
332	Invasive aspergillosis before allogeneic hematopoietic stem cell transplantation: 10-year experience at a single transplant center. Biology of Blood and Marrow Transplantation, 2004, 10, 494-503.	2.0	132
333	Radioimmunotherapy with Bismuth-213 as Conditioning for Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation in Dogs: A Dose Deescalation Study. Transplantation, 2004, 78, 352-359.	0.5	25
334	Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: a study of 193 patients. Blood, 2004, 103, 78-84.	0.6	151
335	Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning. Blood, 2004, 103, 790-795.	0.6	124
336	Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood, 2004, 104, 2254-2262.	0.6	226
337	Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood, 2004, 104, 3535-3542.	0.6	248
338	Conversion of Low Donor Chimerism Following Nonmyeloablative Conditioning for Hematopoietic Cell Transplantation (HCT) Using Pentostatin and Donor Lymphocyte Infusion (DLI).. Blood, 2004, 104, 186-186.	0.6	4
339	Non-Ablative or Reduced Intensity Conditioning Regimens with Volunteer Unrelated Donor Progenitor Cell Transplantation.. Blood, 2004, 104, 2751-2751.	0.6	1
340	Higher Doses of Transplanted CD34+, CD3+ and CD8+ Cells Are Associated with Better Donor T-Cell Chimerism and Less Graft Rejection, but Not with GVHD after Nonmyeloablative Conditioning for Unrelated Hematopoietic Cell Transplantation.. Blood, 2004, 104, 2753-2753.	0.6	1
341	Nonmyeloablative Unrelated Donor Hematopoietic Cell Transplantation (HCT) for Patients (pts) with Poor Risk, Relapsed or Refractory Multiple Myeloma.. Blood, 2004, 104, 2756-2756.	0.6	2
342	Treatment for Acute Myelogenous Leukemia by Low Dose Irradiation Based Conditioning and Hematopoietic Cell Transplantation from Related and Unrelated Donors.. Blood, 2004, 104, 3074-3074.	0.6	2

#	ARTICLE	IF	CITATIONS
343	Nonmyeloablative Conditioning and Hematopoietic Cell Transplantation (HCT) from HLA-Matched Related or Unrelated Donors for Chemotherapy-Refractory Chronic Lymphocytic Leukemia (CLL).. Blood, 2004, 104, 2323-2323.	0.6	4
344	Myeloablative Versus Nonmyeloablative Hemopoietic Cell Transplantation (HCT) for Patients with Myelodysplasia (MDS) or AML with Multilineage Dysplasia Following MDS (tAML).. Blood, 2004, 104, 2320-2320.	0.6	0
345	A Modified Hematopoietic Cell Transplantation (HCT)-Specific-Comorbidity Index.. Blood, 2004, 104, 1146-1146.	0.6	3
346	Prognostic Relevance of "Early-Onset" Graft-Versus-Host Disease Following Nonmyeloablative Hematopoietic Cell Transplantation.. Blood, 2004, 104, 423-423.	0.6	0
347	Comparison of Lung Function after Nonmyeloablative Versus Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation.. Blood, 2004, 104, 5105-5105.	0.6	0
348	Non-Myeloablative Allografting from HLA-Identical Sibling Donors for Treatment of CML.. Blood, 2004, 104, 2316-2316.	0.6	1
349	Dog leukocyte antigen-haploidentical stem cell allografts after anti-CD44 therapy and reduced-intensity conditioning in a preclinical canine model. Experimental Hematology, 2003, 31, 168-175.	0.2	22
350	Immunologic recovery after hematopoietic cell transplantation with nonmyeloablative conditioning. Experimental Hematology, 2003, 31, 941-952.	0.2	96
351	Relapse or progression after hematopoietic cell transplantation using nonmyeloablative conditioning: effect of interventions on outcome. Experimental Hematology, 2003, 31, 974-980.	0.2	26
352	Non-myeloablative allografting from human leucocyte antigen-identical sibling donors for treatment of acute myeloid leukaemia in first complete remission. British Journal of Haematology, 2003, 120, 281-288.	1.2	90
353	Impact of unrelated donor status on the incidence and outcome of cytomegalovirus infections after non-myeloablative allogeneic stem cell transplantation. British Journal of Haematology, 2003, 123, 662-670.	1.2	31
354	Allografting after nonmyeloablative conditioning as a treatment after a failed conventional hematopoietic cell transplant. Biology of Blood and Marrow Transplantation, 2003, 9, 266-272.	2.0	31
355	Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood, 2003, 102, 756-762.	0.6	531
356	Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood, 2003, 102, 3912-3918.	0.6	255
357	Reduced Toxicity and Prompt Engraftment After Minimal Conditioning of a Patient With Fanconi Anemia Undergoing Hematopoietic Stem Cell Transplantation From an HLA-Matched Unrelated Donor. Journal of Pediatric Hematology/Oncology, 2003, 25, 581-583.	0.3	13
358	Dog leukocyte antigen nonidentical unrelated canine marrow grafts: enhancement of engraftment by CD4 and CD8 T cells. Transplantation, 2003, 76, 474-480.	0.5	13
359	Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood, 2003, 101, 1620-1629.	0.6	424
360	Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood, 2003, 102, 3447-3454.	0.6	382

#	ARTICLE	IF	CITATIONS
361	Selective T-cell ablation with bismuth-213 <sup>Bi</sup> -labeled anti-TCR $\beta$ as nonmyeloablative conditioning for allogeneic canine marrow transplantation. <i>Blood</i> , 2003, 101, 5068-5075.	0.6	65
362	Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. <i>Blood</i> , 2003, 102, 827-833.	0.6	432
363	HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. <i>Blood</i> , 2003, 102, 2021-2030.	0.6	320
364	Risks and outcomes of idiopathic pneumonia syndrome after nonmyeloablative and conventional conditioning regimens for allogeneic hematopoietic stem cell transplantation. <i>Blood</i> , 2003, 102, 2777-2785.	0.6	249
365	Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. <i>Blood</i> , 2002, 99, 1978-1985.	0.6	220
366	Bismuth 213 <sup>Bi</sup> -labeled anti-CD45 radioimmunoconjugate to condition dogs for nonmyeloablative allogeneic marrow grafts. <i>Blood</i> , 2002, 100, 318-326.	0.6	86
367	Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome after conditioning with busulfan and fractionated total body irradiation is associated with low relapse rate but considerable nonrelapse mortality. <i>Biology of Blood and Marrow Transplantation</i> , 2002, 8, 161-169.	2.0	66
368	Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: A matched control study. <i>Biology of Blood and Marrow Transplantation</i> , 2002, 8, 512-520.	2.0	236
369	Type of post-grafting immunosuppression after non-myeloablative blood cell transplantation may influence risk of delayed haemolysis due to minor abo incompatibility. <i>British Journal of Haematology</i> , 2002, 116, 500-501.	1.2	13
370	Engraftment of early erythroid progenitors is not delayed after non-myeloablative major ABO-incompatible haematopoietic stem cell transplantation. <i>British Journal of Haematology</i> , 2002, 119, 740-750.	1.2	29
371	Nonmyeloablative hematopoietic cell transplantation: status quo and future perspectives. <i>Journal of Clinical Immunology</i> , 2002, 22, 70-74.	2.0	28
372	Theratope <sup>®</sup> vaccine (STn-KLH). <i>Expert Opinion on Biological Therapy</i> , 2001, 1, 881-891.	1.4	45
373	Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. <i>Blood</i> , 2001, 97, 3390-3400.	0.6	1,306
374	Engraftment of DLA-haploidentical marrow with ex vivo expanded, retrovirally transduced cytotoxic T lymphocytes. <i>Blood</i> , 2001, 98, 3447-3455.	0.6	11
375	Decreased transfusion requirements for patients receiving nonmyeloablative compared with conventional peripheral blood stem cell transplants from HLA-identical siblings. <i>Blood</i> , 2001, 98, 3584-3588.	0.6	101
376	Differential L-Selectin Binding Activities of Human Hematopoietic Cell L-Selectin Ligands, HCELL and PSGL-1. <i>Journal of Biological Chemistry</i> , 2001, 276, 47623-47631.	1.6	48
377	Nonmyeloablative Hematopoietic Cell Transplantation. <i>Annals of the New York Academy of Sciences</i> , 2001, 938, 328-339.	1.8	65
378	Nonmyeloablative hematopoietic stem cell allografting. <i>Current Opinion in Organ Transplantation</i> , 2000, 5, 366-371.	0.8	2

#	ARTICLE	IF	CITATIONS
379	Antibody engagement of intercellular adhesion molecule 3 triggers apoptosis of normal and leukaemic myeloid marrow cells. <i>British Journal of Haematology</i> , 2000, 108, 157-166.	1.2	7
380	Anti-tumor activity of an ICAM-3 antibody (ICM3) Against human leukemic xenograft tumors in nude mice. <i>Experimental Hematology</i> , 2000, 28, 59-60.	0.2	0
381	Mixed Hematopoietic Chimerism after Marrow Allografts Transplantation in the Ambulatory Care Setting. <i>Annals of the New York Academy of Sciences</i> , 1999, 872, 372-376.	1.8	50
382	THE USE OF AN ANTI-TCR???? MONOCLONAL ANTIBODY TO CONTROL HOST-VERSUS-GRAFT REACTIONS IN CANINE MARROW ALLOGRAFT RECIPIENTS CONDITIONED WITH LOW DOSE TOTAL BODY IRRADIATION1. Transplantation, 1999, 67, 1329-1335.	0.5	24
383	Current and Future Preparative Regimens for Bone Marrow Transplantation in Thalassemia. <i>Annals of the New York Academy of Sciences</i> , 1998, 850, 276-287.	1.8	33
384	Contributions of a Highly Conserved VH/VL Hydrogen Bonding Interaction to scFv Folding Stability and Refolding Efficiency. <i>Biophysical Journal</i> , 1998, 75, 1473-1482.	0.2	53
385	Characterization of Monoclonal Antibodies That Recognize Canine CD34. <i>Blood</i> , 1998, 91, 1977-1986.	0.6	85
386	Decreased Rejection and Improved Survival of First and Second Marrow Transplants for Severe Aplastic Anemia (A 26-Year Retrospective Analysis). <i>Blood</i> , 1998, 92, 2742-2749.	0.6	70
387	An anti-CD44 antibody does not enhance engraftment of DLA-identical marrow after low-dose total body irradiation. <i>Transplant Immunology</i> , 1996, 4, 271-274.	0.6	3
388	Transplantation of Allogeneic Peripheral Blood Stem Cells Mobilized by Recombinant Human Granulocyte Colony Stimulating Factor. <i>Stem Cells</i> , 1996, 14, 90-105.	1.4	77
389	CD8+ ACTIVATED T LYMPHOCYTES PRODUCE AN IN VITRO SKIN GRAFT-VERSUS-HOST REACTION IN AN ORGANOTYPIC SKIN CULTURE MODEL. <i>Transplantation</i> , 1995, 59, 69-78.	0.5	1
390	Mechanisms of Enhancement of Natural Killer Activity by an Antibody to CD44: Increase in Conjugate Formation and Release of Tumor Necrosis Factor $\alpha$ . <i>Cellular Immunology</i> , 1995, 164, 255-264.	1.4	19
391	Characterization of an Anti-Cd44 Single-Chain F <sub>v</sub> Antibody That Stimulates Natural Killer Cell Activity and Induces TNF $\alpha$ Release. <i>Immunological Investigations</i> , 1995, 24, 907-926.	1.0	7
392	Prevention of Graft-versus-Host Disease.. <i>Annals of the New York Academy of Sciences</i> , 1995, 770, 149-164.	1.8	21
393	FAILURE OF ANTI-Ia MONOCLONAL ANTIBODY TO ABROGATE TRANSFUSION-INDUCED SENSITIZATION AND PREVENT MARROW GRAFT REJECTION IN DLA-IDENTICAL CANINE LITTERMATES. <i>Transplantation</i> , 1988, 45, 505.	0.5	5
394	Reduced-intensity Conditioning Followed by Hematopoietic Cell Transplantation for Hematologic Malignancies. , 0, , 1043-1058.		5